IJIREEICE ISSN (O) 2321-2004, ISSN (P) 2321-5526

International Journal of Innovative Research in Electrical, Electronics, Instrumentation and Control Engineering

Impact Factor 8.021 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 12, Issue 7, July 2024

DOI: 10.17148/IJIREEICE.2024.12701

AI in Genomic Data Analysis for Drug Development

Shanavaz Mohammed

School of Computer and Information Sciences, University of the Cumberlands, Williamsburg, KY-USA

Abstract: The drug development industry has greatly benefitted from the application of artificial intelligence (AI) in genomic data analysis. Genomic data is useful in understanding diseases genetics as well as in making drugs to counter the diseases. However, this process is quite challenging as it requires a lot of data and analysis which makes the process complex. This aspect of the study made the process to be time-consuming and quite resource intensive which necessitated a better and more efficient tool for analysis. AI has advanced machine learning and deep learning algorithms that enable it to be an effective option in the process. AI offers great solutions for processing large sets of data with efficient and accurate outcomes. As such, the drug development industry has benefited from reduced costs, saving time, and accurate and more effective research data. It has also ensured that therapies are tailor-made for the patients, including making appropriate treatments for the specific genetic profile, ensuring better treatment outcomes. It is therefore without doubt that artificial intelligence has been a great transformative force in the industry and continues to facilitate innovation and advancement in the process.

Keywords: Genomic data, drug discovery, genetics, machine learning.

I. INTRODUCTION

Drug development process is a lengthy and time-consuming venture that requires a lot of resources and analysis of data. Genomic data has been instrumental in providing insight into drug development procedures where it has allowed for proper and effective therapies. Genomic data can be termed as information that describes the functioning of an organism and its functions. This includes information such as molecular sequence in the genes [17]. Understanding this data has ensured that drug development is more effective as it targets specific diseases genomes. Genomic data has allowed researchers to identify potential drug targets and understand patient-specific responses to treatments. Artificial Intelligence has the capacity to analyze big data pertaining to genomes which has also proven to be helpful in genomic data analysis. Machine learning has been very instrumental in programming algorithms to study genome pattern as well as uncover genetic markers with accuracy and effectively [6]. Therefore, the use of AI in genomic data analysis has increased the drug development efficiency and reduced time of developing drugs. This analysis takes a look at how AI has revolutionized genomic data analysis, significantly enhancing drug development by improving data processing, identifying genetic markers, and predicting drug responses.

II. THE ROLE OF GENOMIC DATA IN DRUG DEVELOPMENT

Genomic data is information that pertains to genetic variations of an organism that can have an influence in the disease's manifestation [15]. This data can be retrieved from the DNA sequence and is quite critical in understanding how diseases mutate as well as how they attack. Genomic data is particularly important to drug development as it helps in the discovering of potential drug targets [11]. Genomics has helped in enhancing the identification process of therapeutic targets which has ensured a more effective drug is developed in a shorter period than before [16]. The ability to tailor drugs to individual genetic profiles not only enhances therapeutic efficacy but also minimizes adverse effects, representing a significant advancement in precision medicine [3].

AI has also enabled target identification and validation of potential drug sources especially from genomic data. With the aid of machine learning, AI has been able to accurately locate and genetic data related to diseases pathways [2]. AI has been able to accelerate the entire process of identification with much accuracy and reduced time. Viable drug targets are easily identified with accuracy that also helps reduce the cost of possible failures in the later drug development stages [18]. A good example of genomics data usefulness is in identification of the right therapy in cancer patients by identifying the current genomic pattern and being able to device the right therapy according to the stage of the chronic disease.

The ability of AI to scan through large data set has enabled researchers to find alternative usages for existing drugs. This has been more so facilitated by integrating genomic data with clinical and molecular information to find better and more

DOI: 10.17148/IJIREEICE.2024.12701

efficient therapeutic uses [12]. Drug repurposing has been a useful tool to combat new strains of existing diseases. This approach not only saves time and reduces the cost associated with drug development but also brings therapies to patients more quickly [4]. For instance, during the COVID 19 pandemic, there was a sense of urgency in order to deal with the high infection and death rates. There was a need to come up with a drug that would counter this [13]. Drug repurposing helped come up with drugs faster that helped reduce the toll of the infections.

Another major use of AI in drug development is in predicting response of a drug with high levels of certainty by analyzing the genomic profile of specific diseases and patients [4]. This has ensured that patient's therapy is tailor made for them such that they can easily get treatments that are effective within a shorter time frame and also at a less costs [1]. This also has proven useful in reducing the adverse effects of drugs in patients by being able to recommend the right drugs [7]. The benefits of this approach are profound, offering the potential for more effective and safer healthcare solutions, and marking a significant shift towards precision medicine in clinical practice.

III. BENEFITS OF AI IN GENOMIC DATA ANALYSIS FOR DRUG DEVELOPMENT

One of the key benefits of AI in genomic data analysis is that it leads to increased speed and efficiency in coming up with drugs. The traditional methods of data analysis in genomics has been very laborious and time consuming as it requires analyzing big junks of data [5]. However, with the introduction of AI and machine learning, computerization has come in handy to reduce the work load as well as save on time of processing large data [10].

This has enabled the identification of patterns and insights that would be impossible to detect manually through human errors. The speedy processing of large data has ensured that the time for genomic analysis is expedited and that drug discovery is hastened even before pandemics hit [14]. By rapidly pinpointing potential drug targets and predicting therapeutic outcomes, AI enables researchers to move from hypothesis to validation much more quickly, ultimately bringing new drugs to market faster [9].

Another benefit has been cost reduction. The use of AI in genome data analysis has increased the efficiency of the process which also leads to cost reductions in comparison to the traditional method of analysis which were laborious and time consuming [15]. The traditional methods of analysis were often extensive in terms of trials and errors that consumed quite a number of financial resources.

AI also reduces these costs by streamlining the analysis process and improving the accuracy of target identification and validation [2]. Having an efficient process will reduce redundancies as well as accelerate the research process. AI technologies enhance the accuracy and precision of genomic data analysis, which is crucial for effective drug development [19]. Traditional manual systems would sometimes miss patterns and correlations in genomic data which can lead to incomplete conclusions [8]. AI through machine programming can identify intricate patterns and thus help in predicting outcomes where human labor would not have.

Lastly, AI in genome analysis has ensured enhanced personalization of treatment therapies which has increased the success of individual patient's treatments [11]. Machine learning has enabled analysis of large data from both the patient and the treatment options. This therefore leads to treatments that take into account the patient's unique genetic makeup. This at the same time, results in therapies that have enhanced personalization which in turn improves the effectiveness of treatments and patient satisfaction and adherence, contributing to overall better health outcomes [7].

IV. CONCLUSION

The drug development industry has greatly benefited from the integration of AI in genomic data analysis. This has been particularly helpful in making it possible for interpretation and analysis of large volumes of data with ease, efficiently and with high accuracy levels. This has in turn lead to faster discovery of new drugs as well as repurposing the existing drugs. It has also led to better personalized therapies and treatment options.

AI has therefore proved to be a crucial addition to the medical industry, and it will continue to revolutionize the future. AI promises to be a driving force for future innovations in healthcare and paving the way for more effective and individualized treatments.

DOI: 10.17148/IJIREEICE.2024.12701

REFERENCES

[1] Ahmed, Z. (2020). Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. *Human genomics*, *14*(1), 35.

[2] Arora, G., Joshi, J., Mandal, R. S., Shrivastava, N., Virmani, R., & Sethi, T. (2021). Artificial intelligence in surveillance, diagnosis, drug discovery and vaccine development against COVID-19. *Pathogens*, *10*(8), 1048.

[3] Bender, A., & Cortés-Ciriano, I. (2021). Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. *Drug discovery today*, *26*(2), 511-524.

[4] Chen, B., Garmire, L., Calvisi, D. F., Chua, M. S., Kelley, R. K., & Chen, X. (2020). Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. *Nature Reviews Gastroenterology & Hepatology*, *17*(4), 238-251.

[5] Chen, W., Liu, X., Zhang, S., & Chen, S. (2023). Artificial intelligence for drug discovery: Resources, methods, and applications. *Molecular Therapy-Nucleic Acids*, *31*, 691-702.

[6] Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022). Machine learning in drug discovery: a review. *Artificial Intelligence Review*, *55*(3), 1947-1999.

[7] Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: machine intelligence approach for drug discovery. *Molecular diversity*, *25*, 1315-1360.

[8] Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: recent advances and future perspectives. *Expert opinion on drug discovery*, *16*(9), 949-959.

[9] Lee, J. W., Maria-Solano, M. A., Vu, T. N. L., Yoon, S., & Choi, S. (2022). Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD). *Biochemical Society Transactions*, *50*(1), 241-252.

[10] Lou, B., & Wu, L. (2021). AI on drugs: Can artificial intelligence accelerate drug development? Evidence from a large-scale examination of bio-pharma firms. *Evidence from a Large-scale Examination of Bio-pharma Firms,(March 15, 2021). MISQ Forthcoming*.

[11] Mak, K. K., Wong, Y. H., & Pichika, M. R. (2023). Artificial intelligence in drug discovery and development. *Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays*, 1-38.

[12] Mohammed, Shanavaz. (2024). The impact of Artificial Intelligence (AI) on Clinical Trial Management. International Journal of Mechatronics and Manufacturing Systems. 13. 10.17148/IJARCCE.2024.13610.

[13] Patel, V., & Shah, M. (2022). Artificial intelligence and machine learning in drug discovery and development. *Intelligent Medicine*, *2*(3), 134-140.

[14] Rajula, H. S. R., Verlato, G., Manchia, M., Antonucci, N., & Fanos, V. (2020). Comparison of conventional statistical methods with machine learning in medicine: diagnosis, drug development, and treatment. *Medicina*, *56*(9), 455.

[15] Rasool, S., Ali, M., Shahroz, H. M., Hussain, H. K., & Gill, A. Y. (2024). Innovations in AI-Powered Healthcare: Transforming Cancer Treatment with Innovative Methods. *BULLET: Jurnal Multidisiplin Ilmu*, *3*(1), 118-128.

[16] Shaheen, M. Y. (2021). Applications of Artificial Intelligence (AI) in healthcare: A review. *ScienceOpen Preprints*.

[17] Sharma, A., Virmani, T., Pathak, V., Sharma, A., Pathak, K., Kumar, G., & Pathak, D. (2022). Artificial intelligence-based data-driven strategy to accelerate research, development, and clinical trials of COVID vaccine. *BioMed research international*, *2022*(1), 7205241.

[18] Tripathi, M. K., Nath, A., Singh, T. P., Ethayathulla, A. S., & Kaur, P. (2021). Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery. *Molecular Diversity*, *25*, 1439-1460.

[19] Zhu, H. (2020). Big data and artificial intelligence modeling for drug discovery. *Annual review of pharmacology and toxicology*, *60*, 573-589.

